C. Schmidt

发表

Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010, PloS one.

Title Phase I safety and immunogenicity evaluation of ADVAX , aMultigenic , DNA-based Clade C / B ' HIV-1 candidate vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010 .

Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on ‘Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines’, 31 January–2 February 2006, IAVI, New York, USA

H. Rees, S. Self, P. Kaleebu, 2007, AIDS.

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.

P. Kaleebu, A. McMichael, S. Wakasiaka, 2008, Vaccine.

Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients

T. Luedde, K. Ivens, E. Königshausen, 2021, American Journal of Transplantation.

Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.

S. McCormack, A. McMichael, J. Weber, 2008, Vaccine.

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults

E. Karita, O. Anzala, J. Eldridge, 2015, PloS one.

In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers

Jill Gilmour, Sandhya Vasan, D. Ho, 2011, PloS one.

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.

G. Pantaleo, A. McMichael, W. Jaoko, 2007, Vaccine.

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.

S. McCormack, S. Rowland-Jones, A. McMichael, 2006, Vaccine.

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.

S. Rowland-Jones, A. McMichael, H. McShane, 2004, The Journal of general virology.

Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa

R. Koup, E. Karita, G. Nabel, 2010, PloS one.

Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

Yang Song, Soe Than, Martin Ho, 2010, PloS one.

Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+ T-Cell Epitopes

Lucy Dorrell, Andrew J. McMichael, Jill Gilmour, 2006, Journal of Virology.

Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients

K. Ivens, H. Schaal, J. Stegbauer, 2021, Kidney360.

Immune response to third SARS‐CoV‐2 vaccination in seronegative kidney transplant recipients: Possible improvement by mycophenolate mofetil reduction

T. Luedde, K. Ivens, E. Königshausen, 2022, medRxiv.

Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.

J. Singer, P. Kaleebu, G. Pantaleo, 2014, The Journal of clinical investigation.

A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.

Philip R. Johnson, S. Kochhar, J. van Lunzen, 2008, AIDS research and human retroviruses.

A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.

Philip R. Johnson, P. Kaleebu, L. Bekker, 2010, AIDS research and human retroviruses.

Reasons for Ineligibility in Phase 1 and 2A HIV Vaccine Clinical Trials at Kenya Aids Vaccine Initiative (KAVI), Kenya

S. Wakasiaka, W. Jaoko, O. Anzala, 2011, PloS one.

Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa

P. Kaleebu, E. Karita, S. Allen, 2014, Human Vaccines & Immunotherapeutics.

Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events

P. Kaleebu, S. Kochhar, J. van Lunzen, 2012, Human vaccines & immunotherapeutics.

P14-09. Use of HIV rapid tests for assessment of persistence of vaccine induced antibodies among HIV vaccine recipients

E. Karita, S. Allen, E. Hunter, 2009, Retrovirology.

Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010, PloS one.

Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine

G. Zaharatos, P. Fast, J. Cox, 2010, PloS one.

A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.

Philip R. Johnson, P. Kaleebu, L. Bekker, 2010, AIDS research and human retroviruses.